Thursday, April 16, 2015 7:45:48 AM
For starters,
CEO revised down 2014 revenue projection twice and missed last projection by over $1 million.
RS is coming per S1 filed in February.
Note holders are not getting paid on time because there is no volume for conversions and no cash for payment.
Cash on hand reduced to under $80K.
52 week low of .000001 (yes, 5 zeros!) and zero volume days and closes under .0001 increasing.
$4 million in outstanding toxic debt obligations that the AS can't cover even half of.
$2.7 million in negative equity.
$1.3 million payroll tax liability.
Financing costs (interest and discounts) of $5 million for 2014 alone.
CEO warns that dilution "will" occur until RS and continue afterward ("substantial dilution").
CEO has stated that he can't find lenders or investors (as if that really needed to be stated).
CEO has stated that if revenue does not improve he will not be able to afford reporting requirements let alone expansion.
All of this can be found in PR's and filings- primarily the 2014 10K and Feb S1. Please report anything not factual to admin for deletion. We don't want untrue promotion junk cluttering the board and fooling unsuspecting investors into buying these no bid shares. lol
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM